According to The Insight Partners’ research, the global Acute Lung Injury Market stood at the valuation of US$ 539.61 million in 2021 and is estimated to reach US$ 741.98 million by 2028 to expand at a CAGR of 4.7% from 2021 to 2028. Increasing prevalence of respiratory diseases and rising geriatric population are the critical factors attributed to market expansion.

Chronic respiratory conditions are associated with the changing size of upper airway lumen, mostly observed in aging population. Lung disorder is the most common medical condition found across the globe. According to the Centers for Disease Control and Prevention (CDC), chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI) are some of the major fatal causes in the US. The most common factors responsible for respiratory disorders worldwide are smoking, infections, and genetic conditions. The World Health Organization (WHO) states that approximately 1.76 million deaths are caused due to lung cancer every year, making it the most lethal infectious disease.

Aging causes the degeneration of various cells and tissues, creating the risk of multiple diseases. The failure of organs such as lungs, heart, and kidneys is more prevalent in elderly people, caused mainly due to changes in composition and metabolic activities. With the increasing age, the organ system efficiency starts weakening and makes the body susceptible to various respiratory diseases and other infections. Thus, acute lung injury (ALI) is associated with morbidity in the geriatric population. The countries such as Canada, the US, France, Germany, India, China, and South Korea are witnessing significant growth in the geriatric population. All these factors are the potential drivers of the global acute lung injury market.

However, the high cost of therapies hinders the global acute lung injury market growth.

On the basis of therapy, the acute lung injury market business sphere is categorized into mechanical ventilation, fluid management, pharmacotherapy, and adjunctive procedures. The mechanical ventilation segment captured 51.54% market share in 2021. It generated US$ 278.11 million in 2021 and is anticipated to garner US$ 377.95 million by 2028 to grow at a CAGR of 4.5% during 2021–2028.

According to end user, the global acute lung injury market is segmented into hospitals, ambulatory surgery centers, and others. With 54.01% market share, the hospitals segment led the business in 2021, amassing US$ 291.44 million. It is slated to accrue US$ 408.24 million by 2028 to rise at an annual growth rate of 4.9% along the forecast period.

Speaking of regional breakdown, North America dominated the business occupying 37.42% market share in 2021. The regional market was valued at US$ 201.93 million in 2021 and is supposed to hit US$ 280.16 million by 2028 to elevate at a CAGR of 4.8% throughout the forecast period. Nevertheless, Asia Pacific witnessed growth at 5.2% CAGR and accumulated the sum of US$ 122.16 million in 2021; it is projected to escalate to US$ 174.61 million by 2028.

The prominent players profiled in the global acute lung injury market report are GlaxoSmithKline PLC; Stemedica Cell Technologies, Inc; Histocell; Apeptico Forschung und Entwicklung GmbH; Windtree Therapeutics, Inc; ReAlta Life Sciences, Inc; Apeiron Biologics AG; Qx Therapeutics, Inc; Angion Biomedica; and Asklepion Pharmaceuticals, LLC.

Browse Complete Report Here @ https://www.theinsightpartners.com/reports/acute-lung-injury-market